If this is where you are
Newly diagnosedReports arriving, no plan yetAlready tested elsewhereYou have results you cannot readOn treatment nowYou want to know it is workingOr
Finished treatmentWatching for anything left behindWorried about familyInherited risk, and relativesWanting a second opinionA decision you are unsure aboutDecide
Blueprint CareThe flagship decision report and a dedicated clinical teamSignalOne free question answered on WhatsApp within four hoursNavigationRecords you already have, turned into a clarity timelineDecipherInterpretation of sequencing already done elsewhereTest
Signature, all tiersSolid tumour and blood cancer panels comparedSignature STb33 genes from a blood drawSignature STb O118 genes from a blood drawSignature STb O+523 genes, with TMB and MSISignature STt OProfiling from an existing tissue blockMonitor
SentinelSerial monitoring while treatment is runningSentinel SolidctDNA monitoring for solid tumoursClearMolecular residual disease surveillanceClear SolidTumour-informed surveillanceProtect
HeritageInherited risk, assessed properlyHeritage CoreA broad inherited-risk assessmentHeritage AdhocFocused testing for named relativesCancer DictionaryWhat is discussed in your specific cancerReference
Cancer DictionaryOne structured entry per cancer typeBiomarker LibraryOne page per marker, in plain languagePatient ResourcesGlossary, guides and how to use themWatch, read and ask
Video LibraryShort explainers, captioned and translatedStoriesPatient and clinician experiences, consentedFAQThe questions we are asked mostCancer Dictionary · Head, neck and thyroid
Squamous cell carcinoma of the head and neck varies by subsite, and HPV status in oropharyngeal cancer defines two groups with markedly different biology and outcomes. Genomic profiling is characterised by tumour suppressor loss rather than actionable driver gain, so profiling changes management less often than in lung cancer, and the immune markers are usually the more consequential result.
Also called Head and neck squamous cell carcinoma, HNSCC, Oral cavity cancer, Oropharyngeal cancer.
Start here
Head and neck cancer is separated first by site and by HPV status, and that separation matters more than any mutation, because HPV-associated oropharyngeal cancer is a different disease with a different outlook.
Squamous cell carcinoma of the head and neck varies by subsite, and HPV status in oropharyngeal cancer defines two groups with markedly different biology and outcomes. Genomic profiling is characterised by tumour suppressor loss rather than actionable driver gain, so profiling changes management less often than in lung cancer, and the immune markers are usually the more consequential result.
01Before any molecular question
Usually established first: the anatomical subsite, HPV or p16 status for oropharyngeal tumours, stage, and whether the disease is resectable. Function matters unusually much in this disease, because treatment affects speaking, swallowing and appearance, and those considerations sit alongside oncological ones rather than after them.
Usually already established
02
The divisions below are not labels. Each one changes what the treatment discussion is actually about.
Oral cavity cancer
The predominant subsite in India, strongly associated with tobacco and areca nut use. Surgery usually leads the discussion.
HPV-associated oropharyngeal cancer
A biologically distinct disease with a substantially better outlook, and the focus of de-escalation research aimed at reducing long-term treatment effects.
HPV-negative oropharyngeal cancer
Behaves like other tobacco-associated head and neck cancers rather than like its HPV-positive counterpart.
Laryngeal and hypopharyngeal cancer
Where organ and function preservation is a central part of the treatment discussion.
Nasopharyngeal carcinoma
A distinct disease associated with Epstein-Barr virus, with its own epidemiology and management. See its own entry.
Recurrent or metastatic disease
Where PD-L1 status and profiling most often enter the discussion.
03What is discussed
TP53 alteration is near-universal in HPV-negative disease. CDKN2A loss, FAT1, NOTCH1 and PIK3CA alterations are frequent, and CCND1 and EGFR amplification occur. Few of these currently translate into approved targeted options, so a comprehensive panel in this disease more often confirms biology than opens a treatment. The exceptions worth looking for are NTRK fusions, mismatch repair deficiency and, in salivary gland tumours, HER2 amplification, androgen receptor expression and NTRK fusions in secretory carcinoma. PD-L1 combined positive score is the marker that most often changes management.
HPV / p16
Defines a distinct disease in the oropharynx. Not a treatment target but the single most important classification.
PD-L1
Reported as a combined positive score. The marker most likely to change the treatment discussion.
TP53
Near-universal in HPV-negative disease. Descriptive.
TMB
Assessed as part of the immunotherapy discussion.
NTRK
Rare, but actionable. Particularly relevant in secretory carcinoma of salivary glands.
HER2 and androgen receptor
Relevant in salivary gland tumours rather than in squamous cell carcinoma.
This is not an exhaustive list, and which markers are relevant depends on the individual case. Not every marker listed is assessed in every patient.
04What is tested, and from what
p16 immunohistochemistry, as a surrogate for HPV, is standard for oropharyngeal tumours. PD-L1 is assessed in recurrent or metastatic disease. Comprehensive genomic profiling is discussed mainly in recurrent or metastatic disease, and expectations are worth setting beforehand: the yield of directly actionable findings in squamous cell carcinoma is lower than in lung adenocarcinoma. Salivary gland tumours are a separate discussion with a higher yield.
Inherited risk is not usually prominent in tobacco-associated head and neck cancer. Fanconi anaemia is a recognised predisposition to early-onset head and neck squamous cell carcinoma, and very young onset without the usual risk factors is a reasonable prompt to consider it.
Cancer genetics and hereditary riskCirculating HPV DNA is under active study in HPV-associated oropharyngeal cancer as a surveillance marker, and is one of the more promising applications of circulating tumour markers in any solid cancer, because the marker is viral and therefore highly specific.
More on ctDNA monitoring05The timing question
Testing that arrives after the decision it was meant to inform has already been made is a common and avoidable problem. This is the sequence in which molecular information tends to become relevant.
06Take these to your team
When a decision is being made
Questions worth raising with a treating team.
At progression, recurrence or resistance
The molecular picture at diagnosis is not always the molecular picture later.
07What shapes eligibility
Trial activity divides sharply along HPV status. De-escalation trials in HPV-associated disease aim to reduce long-term toxicity; intensification and novel-agent trials dominate in HPV-negative disease. PD-L1 status and prior therapy commonly determine eligibility.
| Term | What it means |
|---|---|
| Subsite | The precise location within the head and neck. It changes both treatment and outlook. |
| p16 | A protein used as a practical surrogate marker for HPV-associated oropharyngeal cancer. |
| Field effect | When a whole area of tissue has been exposed to a carcinogen, raising the risk of further primary cancers. |
| De-escalation | Reducing treatment intensity to lower long-term harm while preserving cure rates. |
| Organ preservation | Treating in a way that avoids removing a structure such as the larynx. |
These are the services most often relevant to this cancer. Which of them applies is a clinical question, not an automatic one.
This entry is educational. It describes what is commonly discussed in this cancer, not what should happen for any individual. Which of it applies depends on the specific diagnosis, stage, prior treatment and the person themselves. Nothing here is a recommendation, and no list of biomarkers here is exhaustive. Decisions belong with a treating team who know the whole case.
Take the next step
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationCommission your decision report and a dedicated clinical team.
Explore Blueprint CareSignal replies to your first question within four hours, at no cost.
Start with Signal